In this study, we used plasmacytoma‐bearing NOD/SCID mice as tumour models and developed CD38 peptide‐engineered EVs (CD38‐EVs) from umbilical cord MSCs to target malignant plasma cells. Here, CD38 is linked to neoplasm.